WhaleQuant.io
Amgen Inc. (AMGN) Corporate Logo

Amgen Inc. (AMGN) Stock Price & Analysis

Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General

Amgen Inc. (AMGN) Profile & Business Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Key Information

Ticker AMGN
Exchange NASDAQ
Official Site https://www.amgen.com
CIK Number 0000318154
View SEC Filings

Market Trend Overview for AMGN

One model, two time views: what the market looks like right now, and where the larger trend is heading over time.

Longer-Term Market Trend (Mid to Long Term)

Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-11-17 (ET)

As of 2026-11-17, AMGN is moving sideways without a clear direction. Over the longer term, the trend remains bullish.

AMGN last closed at 457.93. The price is about 0.1 ATR above its recent average price (456.33), and the market is currently in a sideways market without a clear direction. Price at 457.93 is moving between minor support near 447.04 and minor resistance near 475.65. Direction remains unclear. View Support & Resistance from Options

The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.

Trend Alignment Summary

Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.

Key Risk Level

A key downside risk boundary is near 419.61. If price falls below this area, the current structure would likely weaken further.

Recent Trend Signal

A systematic trend-activation signal was most recently triggered on 2026-09-25, reflecting a technical shift toward positive directional alignment.

Unusual Price Movement

[2026-11-16] Price moved quickly and looked strong, but participation was limited.

Recent Price Behavior

Recent price action continues to trend lower in a relatively orderly manner, with no clear signs of structural stabilization yet emerging.

Overnight Positioning

There was no clear sign of meaningful positions being carried into the overnight session.

Next-day directional probability forecast Last updated: 2026-11-17 (ET)
Next-session outlook for 2026-11-18 (ET)
No clear next-day edge

What the model sees

The model stays neutral because the setup is not clear enough to justify a directional deployment.


Why the model says this

The model does not deploy this setup because predictability is still too low and price is still close to a gamma transition zone. Predictability is 27%, agreement is 76%, and reversal risk is 28%.

NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history

Recent Cost Distribution Last updated: 2026-11-17 (ET)

This estimate uses 1-minute price, volume, and VWAP data from the last 55 trading days, with turnover-based decay. The sample period is 2026-09-01 to 2026-11-17. The current price is 457.93, 7.25% above the estimated average cost of 426.97. An estimated 74.9% of recent positioning is below the current price, while 24.8% is above it. The peak-density price is 403.00. The largest concentrated cost region is 401.25 to 418.25 and contains 22.9% of the estimated distribution. The nearest region below the current price is 446.75 to 448.75. The nearest region above the current price is 459.75 to 470.75.

Short Interest & Covering Risk for AMGN

This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.

Squeeze Score 0.57

Shows how likely a short squeeze may be under current market conditions.

Key Market Risk Indicators
Short Crowding (Short Interest / Float) 2.33%
Short Positions Trend Not Increasing
Liquidity Trend (Average Daily Volume) -10.96%
20-Day Return 4.33%
Price vs 20-Day High Below Recent Highs

Short Exposure Percentile

Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 20%)

Structure Analysis

AMGN Short positioning looks normal. Current days to cover is 5.0 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 6/100, DTC percentile 55%) and liquidity softening modestly (volume -11%).

Risk Summary

No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.

Why Price Reactions May Be Stronger?

Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.


Note: Short interest data is reported every two weeks by FINRA. The most recent snapshot is 2026-10-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.

Analytical Modules